Smart home monitoring could help pancreatic cancer patients avoid hospital stays
NCT ID NCT04263948
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 34 times
Summary
This study tested a home monitoring system for people with advanced pancreatic cancer receiving a strong chemotherapy called mFOLFIRINOX. The system tracked symptoms, activity, sleep, and weight using connected devices and an online platform. The goal was to see if early alerts could help doctors respond quickly to side effects and reduce emergency hospital visits. The study involved 58 patients in France over 7 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinique du Mousseau
Évry, IDF, 91000, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PiCaDo telemonitoring system (device and internet platform)
What this could lead to
If successful, this could help doctors detect problems earlier in pancreatic cancer patients on chemotherapy, potentially reducing emergency hospital visits and improving quality of life.
What could go wrong
This is a small, completed study with only 58 participants, so results may not apply to all patients. The monitoring system itself does not treat the cancer, and technical issues or patient non-use could limit its effectiveness.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.